EC: 1.1.1.357
3alpha-hydroxysteroid 3-dehydrogenase (3alpha-hydroxysteroid:NAD(P)+ 3-oxidoreductase)
Pathways
| pathway id | name |
|---|---|
| BioCyc:HUMAN_PWY-7455 | allopregnanolone biosynthesis |
| BioCyc:HUMAN_PWY66-378 | androgen biosynthesis |
| BioCyc:META_PWY66-378 | androgen biosynthesis |
| BioCyc:META_PWY-7455 | allopregnanolone biosynthesis |
| Reactome:R-HSA-9757110 | Prednisone ADME |
| Reactome:R-HSA-9748784 | Drug ADME |
| Reactome:R-HSA-5362517 | Signaling by Retinoic Acid |
| Reactome:R-HSA-556833 | Metabolism of lipids |
| Reactome:R-HSA-8978868 | Fatty acid metabolism |
| Reactome:R-HSA-2162123 | Synthesis of Prostaglandins (PG) and Thromboxanes (TX) |
| Reactome:R-HSA-9006931 | Signaling by Nuclear Receptors |
| Reactome:R-HSA-5365859 | RA biosynthesis pathway |
| Reactome:R-HSA-1430728 | Metabolism |
| Reactome:R-HSA-2142753 | Arachidonate metabolism |
| Reactome:R-HSA-162582 | Signaling Pathways |
| WikiPathways:WP5280 | Glucocorticoid biosynthesis |
| WikiPathways:WP5176 | Disorders of bile acid synthesis and biliary transport |
| WikiPathways:WP4524 | Alternative pathway of fetal androgen synthesis |
| PathBank:SMP0030406 | Androstenedione Metabolism |
| PathBank:SMP0000083 | Acetylsalicylic Acid Action Pathway |
| PathBank:SMP0000087 | Rofecoxib Action Pathway |
| PathBank:SMP0000094 | Sulindac Action Pathway |
| PathBank:SMP0000373 | Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency |
| PathBank:SMP0000318 | Congenital Bile Acid Synthesis Defect Type III |
| PathBank:SMP0000104 | Indomethacin Action Pathway |
| PathBank:SMP0000120 | Naproxen Action Pathway |
| PathBank:SMP0000106 | Meloxicam Action Pathway |
| PathBank:SMP0000576 | 21-Hydroxylase Deficiency (CYP21) |
| PathBank:SMP0000693 | Antrafenine Action Pathway |
| PathBank:SMP0000697 | Flurbiprofen Action Pathway |
| PathBank:SMP0000701 | Phenylbutazone Action Pathway |
| PathBank:SMP0000705 | Tiaprofenic Acid Action Pathway |
| PathBank:SMP0000709 | Salicylic Acid Action Pathway |
| PathBank:SMP0000718 | 3-beta-Hydroxysteroid Dehydrogenase Deficiency |
| PathBank:SMP0000035 | Bile Acid Biosynthesis |
| PathBank:SMP0000075 | Arachidonic Acid Metabolism |
| PathBank:SMP0000086 | Ibuprofen Action Pathway |
| PathBank:SMP0000093 | Diclofenac Action Pathway |
| PathBank:SMP0000098 | Ketorolac Action Pathway |
| PathBank:SMP0000314 | Congenital Bile Acid Synthesis Defect Type II |
| PathBank:SMP0000315 | Cerebrotendinous Xanthomatosis (CTX) |
| PathBank:SMP0000102 | Bromfenac Action Pathway |
| PathBank:SMP0000114 | Nabumetone Action Pathway |
| PathBank:SMP0000575 | 11-beta-Hydroxylase Deficiency (CYP11B1) |
| PathBank:SMP0000692 | Antipyrine Action Pathway |
| PathBank:SMP0000696 | Fenoprofen Action Pathway |
| PathBank:SMP0000700 | Lornoxicam Action Pathway |
| PathBank:SMP0000704 | Tolmetin Action Pathway |
| PathBank:SMP0000708 | Salicylate-Sodium Action Pathway |
| PathBank:SMP0000717 | Apparent Mineralocorticoid Excess Syndrome |
| PathBank:SMP0000130 | Steroidogenesis |
| PathBank:SMP0000077 | Piroxicam Action Pathway |
| PathBank:SMP0000084 | Etodolac Action Pathway |
| PathBank:SMP0000371 | Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH |
| PathBank:SMP0000317 | Familial Hypercholanemia (FHCA) |
| PathBank:SMP0000109 | Mefenamic Acid Action Pathway |
| PathBank:SMP0000289 | Diflunisal Action Pathway |
| PathBank:SMP0000116 | Valdecoxib Action Pathway |
| PathBank:SMP0000577 | Corticosterone Methyl Oxidase I Deficiency (CMO I) |
| PathBank:SMP0000650 | Doxorubicin Metabolism Pathway |
| PathBank:SMP0000694 | Carprofen Action Pathway |
| PathBank:SMP0000698 | Magnesium Salicylate Action Pathway |
| PathBank:SMP0000702 | Nepafenac Action Pathway |
| PathBank:SMP0000706 | Tenoxicam Action Pathway |
| PathBank:SMP0000710 | Acetaminophen Action Pathway |
| PathBank:SMP0000353 | Leukotriene C4 Synthesis Deficiency |
| PathBank:SMP0000085 | Ketoprofen Action Pathway |
| PathBank:SMP0000096 | Celecoxib Action Pathway |
| PathBank:SMP0000372 | Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency |
| PathBank:SMP0000316 | Zellweger Syndrome |
| PathBank:SMP0000101 | Suprofen Action Pathway |
| PathBank:SMP0000113 | Oxaprozin Action Pathway |
| PathBank:SMP0000566 | 17-alpha-Hydroxylase Deficiency (CYP17) |
| PathBank:SMP0000578 | Corticosterone Methyl Oxidase II Deficiency (CMO II) |
| PathBank:SMP0000695 | Etoricoxib Action Pathway |
| PathBank:SMP0000699 | Lumiracoxib Action Pathway |
| PathBank:SMP0000703 | Trisalicylate-Choline Action Pathway |
| PathBank:SMP0000707 | Salsalate Action Pathway |
| PathBank:SMP0000720 | 27-Hydroxylase Deficiency |